Headquartered in Horsham, PA, Clinical Ink offers data certainty from source to submission during clinical trials. The company’s Lumenis eSource clinical technology is a suite of solutions for capturing and integrating clinical trial electronic study data from sites, clinicians, and patients in real time. Through configurable direct data capture (DDC), electronic clinical outcome assessment (eCOA), electronic patient reported outcomes (ePRO), and eConsent modules, the company’s eSource Ecosystem has been deployed across 300 studies, in all Phases (I–IV).

Investment Details

Initial Investment Date: August 2020
GI Role: Lead Investor
Status: Current

Associated News